

# Matthew Campbell

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8772445/publications.pdf>

Version: 2024-02-01

92  
papers

10,071  
citations

109321

35  
h-index

49909

87  
g-index

99  
all docs

99  
docs citations

99  
times ranked

20320  
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	9.1	4,701
2	Social stress induces neurovascular pathology promoting depression. <i>Nature Neuroscience</i> , 2017, 20, 1752-1760.	14.8	617
3	The dynamic blood-brain barrier. <i>FEBS Journal</i> , 2015, 282, 4067-4079.	4.7	433
4	NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components. <i>Nature Medicine</i> , 2012, 18, 791-798.	30.7	365
5	Claudin-5: gatekeeper of neurological function. <i>Fluids and Barriers of the CNS</i> , 2019, 16, 3.	5.0	304
6	Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives. <i>Journal of Inflammation Research</i> , 2015, 8, 15.	3.5	263
7	Tight junction modulation of the blood brain barrier: CNS delivery of small molecules. <i>Tissue Barriers</i> , 2016, 4, e1138017.	3.2	183
8	The Blood-Retina Barrier. <i>Advances in Experimental Medicine and Biology</i> , 2013, , 70-84.	1.6	182
9	Blood-brain barrier regulation in psychiatric disorders. <i>Neuroscience Letters</i> , 2020, 726, 133664.	2.1	178
10	Dose-dependent expression of claudin-5 is a modifying factor in schizophrenia. <i>Molecular Psychiatry</i> , 2018, 23, 2156-2166.	7.9	148
11	Autoregulated paracellular clearance of amyloid- $\beta^2$ across the blood-brain barrier. <i>Science Advances</i> , 2015, 1, e1500472.	10.3	113
12	Wnt Signaling Mediates Pathological Vascular Growth in Proliferative Retinopathy. <i>Circulation</i> , 2011, 124, 1871-1881.	1.6	108
13	Tight Junctions of the Outer Blood Retina Barrier. <i>International Journal of Molecular Sciences</i> , 2020, 21, 211.	4.1	104
14	RNAi-mediated reversible opening of the blood-brain barrier. <i>Journal of Gene Medicine</i> , 2008, 10, 930-947.	2.8	102
15	Targeted suppression of claudin-5 decreases cerebral oedema and improves cognitive outcome following traumatic brain injury. <i>Nature Communications</i> , 2012, 3, 849.	12.8	102
16	Blood-brain Barrier Dysfunction as a Hallmark Pathology in Chronic Traumatic Encephalopathy. <i>Journal of Neuropathology and Experimental Neurology</i> , 2016, 75, 656-662.	1.7	98
17	Dynamic Blood-brain Barrier Regulation in Mild Traumatic Brain Injury. <i>Journal of Neurotrauma</i> , 2020, 37, 347-356.	3.4	97
18	Blood-brain barrier associated tight junction disruption is a hallmark feature of major psychiatric disorders. <i>Translational Psychiatry</i> , 2020, 10, 373.	4.8	95

#	ARTICLE	IF	CITATIONS
19	IL-18 Attenuates Experimental Choroidal Neovascularization as a Potential Therapy for Wet Age-Related Macular Degeneration. <i>Science Translational Medicine</i> , 2014, 6, 230ra44.	12.4	87
20	The blood-retina barrier: tight junctions and barrier modulation. <i>Advances in Experimental Medicine and Biology</i> , 2012, 763, 70-84.	1.6	85
21	Differential Apicobasal VEGF Signaling at Vascular Blood-Neural Barriers. <i>Developmental Cell</i> , 2014, 30, 541-552.	7.0	79
22	Vascular and blood-brain barrier-related changes underlie stress responses and resilience in female mice and depression in human tissue. <i>Nature Communications</i> , 2022, 13, 164.	12.8	75
23	NLRP3 Inflammasome and Pathobiology in AMD. <i>Journal of Clinical Medicine</i> , 2015, 4, 172-192.	2.4	74
24	An experimental platform for systemic drug delivery to the retina. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 17817-17822.	7.1	71
25	<sc>IL</sc>1 $\beta$ and inflammasome-independent <sc>IL</sc>1 $\beta$ promote neutrophil infiltration following alum vaccination. <i>FEBS Journal</i> , 2016, 283, 9-24.	4.7	60
26	Therapeutic potential of AAV-mediated MMP-3 secretion from corneal endothelium in treating glaucoma. <i>Human Molecular Genetics</i> , 2017, 26, 1230-1246.	2.9	60
27	Therapeutic benefit derived from RNAi-mediated ablation of IMPDH1 transcripts in a murine model of autosomal dominant retinitis pigmentosa (RP10). <i>Human Molecular Genetics</i> , 2008, 17, 2084-2100.	2.9	58
28	The blood-brain barrier in health and disease. <i>FEBS Journal</i> , 2023, 290, 878-891.	4.7	58
29	Tight junction modulation at the blood-brain barrier: Current and future perspectives. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2020, 1862, 183298.	2.6	51
30	Reversibly Modulating the Blood-Brain Barrier by Laser Stimulation of Molecular-Targeted Nanoparticles. <i>Nano Letters</i> , 2021, 21, 9805-9815.	9.1	49
31	Interleukin-33 regulates tissue remodelling and inhibits angiogenesis in the eye. <i>Journal of Pathology</i> , 2017, 241, 45-56.	4.5	47
32	Microvascular stabilization via blood-brain barrier regulation prevents seizure activity. <i>Nature Communications</i> , 2022, 13, 2003.	12.8	47
33	Prevention of autosomal dominant retinitis pigmentosa by systemic drug therapy targeting heat shock protein 90 (Hsp90). <i>Human Molecular Genetics</i> , 2010, 19, 4421-4436.	2.9	44
34	Systemic low-molecular weight drug delivery to preselected neuronal regions. <i>EMBO Molecular Medicine</i> , 2011, 3, 235-245.	6.9	42
35	Slow blood-to-brain transport underlies enduring barrier dysfunction in American football players. <i>Brain</i> , 2020, 143, 1826-1842.	7.6	42
36	SARM1 deficiency promotes rod and cone photoreceptor cell survival in a model of retinal degeneration. <i>Life Science Alliance</i> , 2020, 3, e201900618.	2.8	42

#	ARTICLE	IF	CITATIONS
37	Endogenous Oils Derived From Human Adipocytes Are Potent Adjuvants That Promote IL-1 $\beta$ -Dependent Inflammation. <i>Diabetes</i> , 2014, 63, 2037-2050.	0.6	38
38	Toll-like Receptor 2 Facilitates Oxidative Damage-Induced Retinal Degeneration. <i>Cell Reports</i> , 2020, 30, 2209-2224.e5.	6.4	36
39	IL-33 deficiency causes persistent inflammation and severe neurodegeneration in retinal detachment. <i>Journal of Neuroinflammation</i> , 2019, 16, 251.	7.2	34
40	Dysregulated claudin-5 cycling in the inner retina causes retinal pigment epithelial cell atrophy. <i>JCI Insight</i> , 2019, 4, .	5.0	33
41	Attenuated CSF $\beta$ R signalling drives cerebrovascular pathology. <i>EMBO Molecular Medicine</i> , 2021, 13, e12889.	6.9	32
42	IL-18 Immunotherapy for Neovascular AMD: Tolerability and Efficacy in Nonhuman Primates. , 2015, 56, 5424.		31
43	Involvement of MAPKs in Endostatin-Mediated Regulation of Blood-Retinal Barrier Function. <i>Current Eye Research</i> , 2006, 31, 1033-1045.	1.5	29
44	Modulating the paracellular pathway at the blood-brain barrier: current and future approaches for drug delivery to the CNS. <i>Drug Discovery Today: Technologies</i> , 2016, 20, 35-39.	4.0	28
45	Blood-brain barrier dysfunction in a boxer with chronic traumatic encephalopathy and schizophrenia. , 2019, 38, 51-58.		28
46	S100B, GFAP, UCH-L1 and NSE as predictors of abnormalities on CT imaging following mild traumatic brain injury: a systematic review and meta-analysis of diagnostic test accuracy. <i>Neurosurgical Review</i> , 2022, 45, 1171-1193.	2.4	28
47	Multi-Directional Dynamic Model for Traumatic Brain Injury Detection. <i>Journal of Neurotrauma</i> , 2020, 37, 982-993.	3.4	27
48	Enhancement of Outflow Facility in the Murine Eye by Targeting Selected Tight-Junctions of Schlemm's Canal Endothelia. <i>Scientific Reports</i> , 2017, 7, 40717.	3.3	25
49	The blood brain barrier: Insights from development and ageing. <i>Tissue Barriers</i> , 2017, 5, e1373897.	3.2	23
50	Current perspectives on established and novel therapies for pathological neovascularization in retinal disease. <i>Biochemical Pharmacology</i> , 2019, 164, 321-325.	4.4	22
51	An eye on the future of inflammasomes and drug development in AMD. <i>Journal of Molecular Medicine</i> , 2013, 91, 1059-1070.	3.9	21
52	Systemic delivery of antagomirs during blood-brain barrier disruption is disease-modifying in experimental epilepsy. <i>Molecular Therapy</i> , 2021, 29, 2041-2052.	8.2	20
53	Claudin-5: A Pharmacological Target to Modify the Permeability of the Blood-Brain Barrier. <i>Biological and Pharmaceutical Bulletin</i> , 2021, 44, 1380-1390.	1.4	20
54	First-in-class thyrotropin-releasing hormone (TRH)-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative models. <i>Neuropharmacology</i> , 2015, 89, 193-203.	4.1	18

#	ARTICLE	IF	CITATIONS
55	Systemic delivery of therapeutics to neuronal tissues: a barrier modulation approach. <i>Expert Opinion on Drug Delivery</i> , 2010, 7, 859-869.	5.0	16
56	Manipulating ocular endothelial tight junctions: Applications in treatment of retinal disease pathology and ocular hypertension. <i>Progress in Retinal and Eye Research</i> , 2018, 62, 120-133.	15.5	16
57	Permeability of the Blood-Brain Barrier after Traumatic Brain Injury: Radiological Considerations. <i>Journal of Neurotrauma</i> , 2022, 39, 20-34.	3.4	16
58	Minocycline suppresses disease-associated microglia (DAM) in a model of photoreceptor cell degeneration. <i>Experimental Eye Research</i> , 2022, 217, 108953.	2.6	15
59	Antioxidant Therapy for Retinal Disease. <i>Advances in Experimental Medicine and Biology</i> , 2014, 801, 783-789.	1.6	14
60	Tight Junctions of the Neurovascular Unit. <i>Frontiers in Molecular Neuroscience</i> , 2021, 14, 752781.	2.9	14
61	Altered expression and interaction of adherens junction proteins in the developing OLM of the Rho( $\alpha^1/\alpha^2$ ) mouse. <i>Experimental Eye Research</i> , 2007, 85, 714-720.	2.6	13
62	Vascular Expression of Permeability-Resistant Occludin Mutant Preserves Visual Function in Diabetes. <i>Diabetes</i> , 2021, 70, 1549-1560.	0.6	13
63	Fibrotic Changes to Schlemm's Canal Endothelial Cells in Glaucoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9446.	4.1	13
64	Recurrent <i>de novo</i> mutations in <i>CLDN5</i> induce an anion-selective blood-brain barrier and alternating hemiplegia. <i>Brain</i> , 2022, 145, 3374-3382.	7.6	13
65	IL-18: a new player in immunotherapy for age-related macular degeneration?. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 1273-1275.	3.0	12
66	Advanced late-onset retinitis pigmentosa with dominant-acting D477G RPE65 mutation is responsive to oral synthetic retinoid therapy. <i>BMJ Open Ophthalmology</i> , 2020, 5, e000462.	1.6	11
67	Inner Blood-Retinal Barrier Regulation in Retinopathies. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1185, 329-333.	1.6	11
68	Age-related changes in eye morphology and aqueous humor dynamics in DBA/2J mice using contrast-enhanced ocular MRI. <i>Magnetic Resonance Imaging</i> , 2019, 59, 10-16.	1.8	10
69	siRNA targeting Schlemm's canal endothelial tight junctions enhances outflow facility and reduces IOP in a steroid-induced OHT rodent model. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 20, 86-94.	4.1	10
70	Reply to IL-18 is not therapeutic for neovascular age-related macular degeneration. <i>Nature Medicine</i> , 2014, 20, 1376-1377.	30.7	8
71	Properties and Therapeutic Implications of an Enigmatic D477G RPE65 Variant Associated with Autosomal Dominant Retinitis Pigmentosa. <i>Genes</i> , 2020, 11, 1420.	2.4	8
72	Reversible and Size-Selective Opening of the Inner Blood-Retina Barrier: A Novel Therapeutic Strategy. <i>Advances in Experimental Medicine and Biology</i> , 2010, 664, 301-308.	1.6	8

#	ARTICLE	IF	CITATIONS
73	Calpain and Photoreceptor Apoptosis. <i>Advances in Experimental Medicine and Biology</i> , 2012, 723, 547-552.	1.6	8
74	Concussion susceptibility is mediated by spreading depolarization-induced neurovascular dysfunction. <i>Brain</i> , 2022, 145, 2049-2063.	7.6	8
75	RNAi-mediated barrier modulation: synergies of the brain and eye. <i>Therapeutic Delivery</i> , 2010, 1, 587-594.	2.2	7
76	An Overview of the Involvement of Interleukin-18 in Degenerative Retinopathies. <i>Advances in Experimental Medicine and Biology</i> , 2014, 801, 409-415.	1.6	7
77	Barrier Modulation in Drug Delivery to the Retina. <i>Methods in Molecular Biology</i> , 2012, 935, 371-380.	0.9	7
78	Inner blood-retina barrier involvement in dry age-related macular degeneration (AMD) pathology. <i>Neural Regeneration Research</i> , 2020, 15, 1656.	3.0	7
79	From RNA interference technology to effective therapy: how far have we come and how far to go?. <i>Therapeutic Delivery</i> , 2011, 2, 1395-1406.	2.2	6
80	Interleukin-33 regulates metabolic reprogramming of the retinal pigment epithelium in response to immune stressors. <i>JCI Insight</i> , 2021, 6, .	5.0	6
81	On Further Development of Barrier Modulation as a Technique for Systemic Ocular Drug Delivery. <i>Advances in Experimental Medicine and Biology</i> , 2012, 723, 155-159.	1.6	5
82	Methamphetamine enhances caveolar transport of therapeutic agents across the rodent blood-brain barrier. <i>Cell Reports Medicine</i> , 2022, 3, 100497.	6.5	4
83	Blood-brain barrier permeability imaging as a predictor for delayed cerebral ischaemia following subarachnoid haemorrhage. A narrative review. <i>Acta Neurochirurgica</i> , 2021, 163, 1457-1467.	1.7	3
84	Interleukin-18 Bioactivity and Dose: Data Interpretation at a Crossroads. <i>Investigative Ophthalmology and Visual Science</i> , 2014, 55, 8349-8350.	3.3	2
85	Fundamentals of Brainâ€“Barrier Anatomy and Global Functions. , 2019, , 3-20.		2
86	Intracameral Delivery of AAV to Corneal Endothelium for Expression of Secretory Proteins. <i>Methods in Molecular Biology</i> , 2019, 1950, 263-270.	0.9	2
87	The Blood-Brain Barrier in Glioblastoma: Pathology and Therapeutic Implications. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2016, , 69-87.	0.1	2
88	SARM1 Promotes Photoreceptor Degeneration in an Oxidative Stress Model of Retinal Degeneration. <i>Frontiers in Neuroscience</i> , 2022, 16, 852114.	2.8	2
89	Author Response: The Role of IL-18 in the Treatment of AMD. , 2015, 56, 8237.		1
90	Pharmacokinetics of Systemic Drug Delivery. , 2019, , 39-56.		0

#	ARTICLE	IF	CITATIONS
91	Molecular Medicines. SpringerBriefs in Genetics, 2012, , 31-46.	0.1	0
92	Decreased CSF1R Signaling and the Accumulation of Reticular Pseudo-Drusen?. Ophthalmic Surgery Lasers and Imaging Retina, 2021, 52, 666-671.	0.7	0